Relation Between Baseline CXCR1 Expression And Neoadjuvant Chemotherapy Response In Breast Cancer Patients

Area of Science:

• Oncology
• Immunology

Background:

• Neoadjuvant chemotherapy is a standard treatment for breast cancer.
• Understanding biomarkers that predict treatment response is crucial for personalized medicine.

Purpose of the Study:

• To investigate the expression of C-X-C Motif Chemokine Receptor 1 (CXCR1) in breast cancer tissues before neoadjuvant chemotherapy.
• To determine the relationship between CXCR1 expression and the effectiveness of neoadjuvant chemotherapy, as well as other prognostic factors.

Main Methods:

• A prospective study involving 100 breast cancer patients undergoing neoadjuvant chemotherapy.
• Immunohistochemical staining was used to assess CXCR1 expression in tumor tissues, categorized as low or high.
• Patients were followed for 2 years to evaluate treatment response, recurrence, and mortality.

Main Results:

• High CXCR1 expression was associated with advanced tumor grade, advanced tumor stage, triple-negative breast cancer, and higher Ki-67 expression.
• Patients with high CXCR1 expression showed a significantly lower frequency of complete pathological response to neoadjuvant chemotherapy (p<0.001).
• Multivariate analysis identified high baseline CXCR1 expression and triple-negative hormonal status as significant predictors of complete pathological response.

Conclusions:

• Baseline CXCR1 expression in breast cancer tissues is significantly associated with pathological response to neoadjuvant therapy.
• CXCR1 may serve as a predictive biomarker for neoadjuvant chemotherapy response in breast cancer patients.